Tumor necrosis factor-α and mortality in heart failure: A community study

Circulation

Volumn 118, Issue 6, 2008, Pages 625-631

  Dunlay, Shannon M ^a   Weston, Susan A ^a   Redfield, Margaret M ^a   Killian, Jill M ^a   Roger, Véronique L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Epidemiology; Heart failure; Inflammation; Risk factors

Indexed keywords

CREATININE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; COMORBIDITY; CREATININE CLEARANCE; FEMALE; HAZARD RATIO; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SURVIVAL RATE; TIME SERIES ANALYSIS; BLOOD; FOLLOW UP; IMMUNOLOGY; INFLAMMATION; KAPLAN MEIER METHOD; MIDDLE AGED; RISK FACTOR; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INFLAMMATION; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MINNESOTA; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50349097674     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.759191     Document Type: Article

References (46)

1. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95(suppl):3C-8C.
2. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes, part I: introduction and cytokines. Circulation. 2006;113:e72-e75.
3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
4. Dutka DP, Elbown JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive heart failure. Br Heart J. 1993;70:141-143.
5. Deswal A, Peterson NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation. 2001;103:2055-2059.
6. Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L, Guevara P, Rebollar V, Granados J. Tumour necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure. Clin Invest Med. 2005;28:23-29.
7. Chung ES, Packer M, Lo KH, Fasanmade AA, Wilkerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation. 2003;107:3133-3140.
8. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuizzen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
9. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results from RECOVER, RENAISSANCE, RENEWAL, and ATTACH. Int J Cardiol. 2002;86:123-130.
10. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209-2216.
11. US Census Bureau state and county QuickFacts. Available at: http://quickfacts.census.gov/qfd/states/27/27109.html. Accessed September 27, 2007.
12. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
13. Pakhomov SV, Buntrock J, Chute CG. Prospective recruitment of patients with congestive heart failure using an ad-hoc binary classifier. J Biomed Inform. 2005;38:145-153.
14. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
15. Lang RM, Biereg M, Devereux RB. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Echocardiography. J Am Soc Echocardiogr. 2005;18:1440-1463.
16. Quinones MA, Waggoner AD, Reduto LA, Nelson JD, Young JB, Winters WL, Ribeiro LG, Miller RR. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation. 1981;64:744-753.
17. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik MM. Clinical utility of doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788-1794.
18. Roger VL, Killian J, Henkel M, Weston SA, Goraya TY, Yawn BP, Kottke TE, Frye RL, Jacobsen SJ. Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol. 2002; 55:593-601.
19. Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard WJ, Hunninghake DB, Illingworth D, Luepker RV, McBride P, McKenney JM, Pasternak RC, Stone NJ, Van Horn L. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:3143-3157.
20. Genuth S, Albert KG, Bennett P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3171.
21. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Nutritional Anemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 1968. WHO Technical Report Series 405.
23. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
25. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95(suppl):9C-16C.
26. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor α therapy and heart failure. Arthritis Rheum. 2004;50:1040-1050.
27. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266:7313-7316.
28. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287.
29. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96: 1042-1052.
30. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
31. Latini R, Bianchi M, Correale E, Dinarello CA, Fantuzzi G, Fresco C, Maggioni A, Mengozzi M, Romano S, Shapiro L, Zironi M, Tognoni G, Turato R, Ghezzi P. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol. 1994;23:1-6.
32. Hattler BG, Zeevi A, Oddis CV, Finkel MS. Cytokine induction during cardiac surgery: analysis of TNF-alpha expression pre and post-cardiopulmonary bypass. J Card Surg. 1995;10:418-422.
33. Torre-Amione G, Kapadia S, Lee J, Bias RD, Liebowitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
34. Bryant D, Becker L, Richardson J, Shelton-1 J, Franco F, Peshock R, Thompson M, Biroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation. 1998;97: 1375-1381.
35. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res. 1997;81:627-635.
36. Sun M, Dawood F, Wen W, Chen M, Dixon I, Krishenbaum LA, Liu PP. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221-3228.
37. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382-1391.
38. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247-1252.
39. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-α mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115:1398-1407.
40. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor α confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 1998;97:1392-1400.
41. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509-518.
42. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Norday I, Aass H, Espevik T, Simonsen S, Froland SS, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376-382.
43. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27: 1201-1206.
44. Greenland P. When is a new prediction marker useful? Arch Intern Med. 2005;165:2454-2456.
45. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
46. Luepker RV, Jacobs DR, Gillum RF, Folsom AR, Prineas RJ, Blackburn H. Population risk of cardiovascular disease: the Minnesota Heart Survey. J Chron Dis. 1985;38:671-682.